PROCESS FOR DETECTION OF NEOPLASTIC DISEASE

Abstract: Processes for detecting the presence of neoplastic disease are provided. The processes involve the detection of a product associated with expression of genes that encode protein receptors for fibroblast growth factor in cells or a product indicative of elevated levels of a fibroblast growth factor receptor in a body fluid. Detection can be carried out in a variety of ways, including hybridization to detect the presence of mRNA encoding a growth factor receptor or immunological assays to detect the presence of receptor protein. Kits for performing the processes are also provided.

Description: PROCESS FOR DETECTION OF NEOPLASTIC DISEASE This invention was made in part with Government support under Grant No. D 1881 1 from the National Institutes of Health. The U.S. Government may have certain rights in this invention. This application is a continuation-in-part of United States Serial No. 07/900,646, filed June 18, 1992, by Michael Philip Nova, Ana-Maria Gonzalez and Andrew Baird, entitled "PROCESS FOR DETECTION OF NEOPLASTIC DISEASE". The disclosure of United States Serial No. 07/900,646 is incorporated herein by reference thereto. FIELD OF THE INVENTION This invention relates to processes for diagnosing cancer. In a more specific aspect it relates to methods for detecting melanoma. BACKGROUND OF THE INVENTION Despite improvements in surgical and radiological procedures and an increasingly large arsenal of drugs for treating cancer, cures for the many malignant neoplastic diseases remain elusive. The strides that have been made in reducing mortality have come largely from education programs that have heightened public awareness of the need for routine physical examination and improved techniques for detecting the presence of neoplastic disease at a sufficiently early stage to provide a favorable prognosis. Such improved techniques include immunoassays for tumor associated antigens, such as carcinoembryonic antigen (CEA) and alphafetoprotein (AFP), and nucleic acid hybridization techniques. Nucleic acid hybridization can be used, for example, to diagnose the presence of chromosomal translocations associated with certain forms of cancer, such chromosomal translocations associated with chronic myelogenous leukemia (CML). Successful techniques, however, are rare. Accordingly, there remains a pressing need for better cancer diagnostics. For example, if detected before metastasis, malignant melanoma is an excellent example of a virulent cancer that is treatable by surgical removal with a high rate of success. After metastasis, however, the five year mortality rate using available chemotherapy and radiotherapy techniques is a shocking 97-99% (6,500 deaths in the United States in 1991 ). The shortcomings of modern treatments for melanoma take on heightened significance when it is appreciated that the incidence of this once relatively rare cancer is increasing annually at a rate of 4-10%, with 32,000 new cases in the United States in 1991. Early detection of melanoma is complicated because many melanomas presented for diagnosis are either atypical in appearance in that they appear identical to non-melanocytic lesions or are obscured by inflammation. Some melanomas are completely amelanotic (non-pigmented) and others are histologically similar to benign melanocytic growths. Thus, using classical histological techniques, it is frequently impossible to determine whether a lesion is actually a melanoma or whether it is a benign melanocytic growth or other type of carcinoma, for example a sarcoma. In many cases, particularly those in which histological examination of biopsy material is used, it remains difficult to classify the kind of tumor which may be present. It is also difficult to differentiate malignancies from benign tumors and other non-malignant tissue abnormalities. Of perhaps even greater consequence to the patient, the techniques that are available lack in sensitivity so that early stage disease, the most opportune time for therapeutic intervention, is often missed entirely. Thus, there is a need for methods for detection neoplasms, including malignant melanoma. In particular there is a need for relatively simple methods that can be used to quickly assess the malignancy of biopsied lesions or to test urine, blood or other body fluids for the a marker indicative of neoplastic disease. Thus far, except in the few instances noted above, reliable means for performing such methods have proved elusive. For example, there have been attempts to develop immunohistochemical tests for diagnosing neoplastic. The resulting tests, however, are often inconclusive, arbitrary and, generally, not diagnostically useful (see, e.g.. Gaffey (1991 ) Amer. J. Clin. Path. 96:679-680). In fact, the search for a reproducible "cancer stain" has been deemed "a Holy Grail" for pathologists (see, Gaffey at page 680). As the foregoing demonstrates, there clearly exists a pressing need for better techniques to detect and classify neoplastic diseases like melanoma. Therefore, it is an object herein to provide methods for early diagnosis of neoplastic disease, including melanoma. In particular, it is an object herein to provide immunohistochemical methods and other methods for the detection of markers in biopsied tissue samples, urine, blood and other body fluids that are indicative of neoplastic disease. SUMMARY OF THE INVENTION Fibroblast growth factor (FGF) is an almost ubiquitous protein that is highly multifunctional and present in many tissues. It has generally been thought to act in vivo on the same cell types in which it acts ]n vitro. As a corollary, it has been assumed that FGF receptors are present jn vivo on the same tissues on which FGF acts in vitro. As described herein, however, contrary to predictions made from the observations made on cells in culture, the receptor for FGF is differentially expressed jn vivo. For example, as described herein, certain neoplastic tissues and cells after injury have elevated levels of receptor when compared to the low to absent levels in non-malignant quiescent tissue. Consequently, as shown herein, the elevated levels of expression of the receptor gene by select neoplasms can be used in the diagnosis of such neoplasms. Accordingly, methods for detecting the presence of neoplastic disease detecting elevated levels of expression of are provided. Such elevated levels may be detected by any suitable method. For example, they can be detected determining the presence of the receptor or its mRNA in cellular material or by determining the presence of the receptor in body fluids as a result of sloughing from tumor cells. Thus, the methods involve the detection of a product associated with expression of a gene, such as mRNA, that encodes a protein receptor for fibroblast growth factor (FGF) or detection of FGF receptor in cells, tissues, or a body fluid, such as, for example, blood, serum or urine. When an assay is performed directly on suspect cells, the target product can be either the messenger RNA (mRNA) transcription product of the gene encoding the receptor, cDNA prepared from the mRNA or the receptor protein. Techniques for detecting mRNA that employ nucleic acid hybridization are useful for directly assaying suspect cells. The hybridization methods may be performed in situ, on mRNA isolated from suspect cells, or on cDNA prepared from the mRNA. Such methods employ nucleic acid probes having a nucleotide sequence that is sufficiently complementary to that of the receptor and of a sufficient length to selectively hybridize to the mRNA or cDNA encoding the receptor to form detectable hybrids. The probe is allowed to bind with the target nucleic acid in a manner that permits detection of the resulting duplex using art established techniques. In the case of body fluids and histopathologic analysis, the target expression product is preferably the receptor protein. Detection of the receptor protein can be accomplished by any technique which is specific for the protein. For example, immunological techniques employing antibodies to the receptor or a portion thereof that form a detectable antibody/receptor complex can be used. The assays herein may be used to detect any neoplasm that results in higher levels of FGF receptor protein or FGF receptor-encoding mRNA in a cell, tissue or body fluid. Such neoplasms include, but are not limited to certain breast cancers, ovarian cancer, prostate hyperplasia, prostate carcinoma, astrocytoma, glioblastoma and malignancies and diseases that are subsequently shown to be associated with elevated FGF receptor expression. For example, as demonstrated below, the detection of a specific FGF receptor or mRNA that encodes the receptor that is associated with malignant melanoma is particularly advantageous since they are increased in amounts when compared to normal or benign lesions. Accordingly, the assay is described below with particular reference to its use for detecting malignant melanoma. In preferred embodiments, assays that distinguish suspect lesions that are malignant melanoma from those that are not are provided, Such assays provide a relatively simple staining procedure for diagnosing early stage malignant melanoma. Kits for use in performing the assays for detection of neoplasms are also provided. DETAILED DESCRIPTION OF THE INVENTION Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference thereto. As used herein, a malignancy or disease that is associated with FGF receptor expression refers to malignancy, such as melanoma, that in some manner results in a detectable increase in the amount of an FGF receptor in a body fluid, tissue or cell. As used herein, "high stringency conditions" means conditions of low salt concentration and elevated temperature whereby the oligonucleotide probe for FGFR anneal to the RNA or cDNA encoding FGFR and not non-specifically to other mRNA, i.e.. selectively and detectably hybridizes to the RNA or cDNA, whereby stable hybrids form, can be detected, and can be correlated with increased expression of mRNA encoding an FGFR. When performing jjn situ hybridization reactions, such conditions must not be sufficiently harsh to harm the tissue. High stringency conditions are set forth in Example 2. As used herein, selectively hybridize means to form hybrids that are sufficiently unique to permit diagnosis of a neoplastic disease. Thus, a probe that selectively hybridizes to DNA encoding a growth factor receptor will form detectable hybrids under the conditions of the assay substantially only with mRNA or cDNA encoding a fibroblast growth factor receptor or with mRNA or cDNA that is substantially homologous to mRNA or cDNA encoding a fibroblast growth factor receptor. As used herein, a blocker is a composition that prevents non¬ specific binding of antibodies to the sample tissue. Such blockers include, but are not limited, to such as 3% normal serum from the same species as the second antibody used in the immunoassay; 2% bovine serum albumin or casein; 1.5% normal horse serum or mixtures of any of the preceding compositions. The particular blocker selected and can be empirically determined for each antibody. Methods for diagnosing neoplastic diseases To practice the methods provided herein, a suitable sample is assayed for the presence of a product indicative of elevated levels of an FGF receptor protein and/or expression of a gene encoding an FGF receptor protein. The receptor (hereinafter referred to as an "FGFR") is a cell surface protein receptor with which an FGF specifically interacts. There are numerous subtypes and isoforms of FGFRs, each potentially specific for a particular cell type, but more highly expressed or shed in malignant than in non-malignant tissue. The target product to be assayed can either be an FGFR, a fragment of an FGFR, mRNA or cDNA encoding an FGFR. These products can be detected by any suitable means for detection of specific amino acid or nucleic acid molecules. Preferred for this purpose are immunological techniques for detecting FGFR and nucleic acid hybridization techniques for detecting mRNA encoding FGFRs. Immunological and hybridization techniques for assaying proteins and mRNA are generally well known in the art and, accordingly, will not be described in detail. Immunological methods Immunological methods are appropriate for detecting FGFRs in body fluids and on cell or tissue surfaces. Antigens An FGF receptor or fragment thereof is an antigen suitable for use in obtaining antibodies useful in the methods. DNA encoding FGF receptors, purified receptors, and methods for obtaining each are known to those of skill in this art. For example, cloning and expression of FGF receptors are described in PCT International Application WO 91/00916 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, July 6, 1989, which is based on U.S. Application Serial No. 07/377,033; Isacchi et al. (1990) "Complete Sequence of a Human Receptor for Acidic and Basic Fibroblast Growth Factors", Nucleic Acid Res. 18:1906; Keifer et aL, (1991 ) "Molecular Cloning of A Human Basic FGF Receptor cDNA and Expression of a Biologically Active Extracellular Domain in a Baculovirus System", Growth Factors 05:115-1 19: Bergonzoni et aL (1992) "Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli". Eur. J. Biochem. 210: 823-829; Seno et aL (1991 ) "Two cDNAs encoding novel human FGF receptor", Biochim. Biophys. Acta 1089:244- 246. See, also Johnson et a (1993) "Structural and Functional Diversity in the FGF Receptor Multigene Family" Advances in Cancer Res. 60:1-41. Fragments of FGFR may also be used as the antigen for production of either monoclonal or polyclonal antibodies to FGFR(s). One such antigen is the extracellular domain of an FGFR. SEQ ID NO. 1 sets forth DNA and the encoded amino acids of a portion of an extracellular domain of an FGFR 1 . SEQ ID NO. 2 sets for the amino acid sequence of the entire extracellular domain of an FGFR 1 that has been used as an antigen in the preparation of monoclonal antibodies for use in the immunoassays described herein. Antibodies Antibodies useful in any of these immunological methods can be either polyclonal or monoclonal in nature and the species of origin, e.g.. rabbit, goat, rat or murine, is not a critical feature of the methods. The preparation of polyclonal and monoclonal antibodies is well known to those of skill in this art (see, e.g.. Goding, J.W. (1986) Monoclonal Antibodies: Principles and Practice. Academic Press, London, NW1 (1986); and Groper, T.G. (1977) The Tools of Biochemistry. John Wiley & Sons, New York). In addition, functional fragments of antibodies such as Fab, (Fab') 2 and peptides having an FGFR binding region can be employed. The means for obtaining such antibodies and fragments are also well known to those skilled in the art and will not be described in detail. Monoclonal antibodies have been prepared using the extracellular domain (SEQ ID NO. 2) of an FGFR 1 as an immunogen. Since portions of the amino acid sequences of extracellular domains are conserved among FGFRI s, monoclonal antibodies raised against this protein should specifically react with the regions of many, if not all, FGFR1 subtypes. Immunoassays The selected antibody or fragment is reacted according to standard immunoassay protocols with serial dilutions of a sample of body fluid, such as urine, blood, a blood fraction or cerebral spinal fluid, or with biopsied tissues. In some instances, mixtures of several antibodies or fragments or antibodies and fragments raised against different FGFR types or subtypes may be used. Competitive immunoassays Immunological techniques that can be used for detecting FGFR in a fluid sample such as blood, serum, cerebral spinal fluid, or urine include, but are not limited to, competitive immunoassays that employ an antibody specific for the receptor. Such assays can also employ a labeled receptor as a second reagent which competes for the captive antibody with receptor present in the sample. The labeled receptor is typically conjugated with a moiety that permits direct or indirect detection. Among the useful labels are radioactive nuclides, such as 35 S, 125 l, 131 l, enzymatic moieties that cause a color change, or luminescence- generating reactions with suitable substrates. Such enzymes include, for example, luciferase, horseradish peroxidase and alkaline phosphatase. Fluorescent labels can also be used. Alternatively, the labeled receptor can be conjugated with a moiety that is recognized by another reagent which permits detection. For example, the receptor can be bound to biotin which will bind to a detectable avidin derivative, e.g.. avidin or a derivative or analog therof, such as, streptavidin, conjugated with an enzyme as described above. Sandwich immunoassays Another immunological process useful for detecting FGFR in fluid samples is the two-site or "sandwich" assay. This assay typically uses two antibody preparations, one of which is specific for FGFR and is bound, or capable of being bound, to a solid phase to separate FGFR from other material present in the sample. The second antibody preparation also binds to FGFR at a different site from the first antibody, and is labeled to permit detection of the antibody (solid phase):FGFR:antibody (labeled) complex after the appropriate contacting of the sample with the antibody reagents. Direct immunostaining A third and presently preferred immunological technique for tissue and cell samples, is the direct immunostaining of sections of biopsy material using anti-FGFR antibodies. This is particularly preferred for detection of melanoma. Frozen section or paraffin-fixed sections can be used. The anti-FGFR antibodies can be directly labeled with an enzyme such as peroxidase in order to generate a color reaction when substrate is added to the section. Preferably, however, the section is incubated with the anti-FGFR antibodies, treated with a biotinylated antibody against the species of origin of the primary antibody, and then exposed to a complex of avidin (or streptavidin) biotin and enzyme to increase the amount of enzyme present on the section and thereby increase the sensitivity of the process. A process for distinguishing melanocytic lesions non-melanocytic lesions using paraffin-fixed sections of biopsy material and monoclonal or polyclonal antibodies to FGFR has been developed. Using a monoclonal antibody that was specific for the extracellular domain of the FGFR and paraffin-fixed biopsied material, malignant lesions were distinguished from non-malignant lesions, thereby providing a relatively simple staining procedure for diagnosing early stage malignant melanoma. Hybridization methods As pointed out above, mRNA isolated from the cell or tissue that expresses the target receptor gene or cDNA prepared from such mRNA is an alternative to the receptor as a target. Hybridization assays can be performed directly on cells or tissue samples or using mRNA isolated from the cells or tissue or cDNA prepared from the mRNA. When an assay is performed directly on suspected cancer cells, a nucleic acid probe having a nucleotide sequence complementary to a target mRNA is added to the cells in a manner which permits the probe to selectively hybridize to mRNA in the target tissue or cell that encodes the receptor. Alternatively, mRNA can be isolated from the target cells, tissues or from a body fluid and hybridized with the probe. In addition, cDNA may be prepared from the mRNA and used as a target. Hybridization reactions are preferably performed under conditions of high stringency, i.e.. conditions that select for hybrids that have less than about 10-15% mismatched sequences. Conditions of lower stringency may be used, when the precise identity of the receptor is not known. When hybridizations are performed in situ, however, the conditions must be carefully controlled to avoid harming the tissue or cells. Such conditions, however, can be determined empirically. Probes The probe may be DNA, such as cDNA, or RNA, such as complementary RNA (i.e.. antisense RNA) that is prepared from DNA that encodes all or a portion of one or more FGF receptors. The length of the probe can be any length adequate to permit a diagnostic result when the selected stringency hybridization conditions, generally high stringency, are used. Accordingly, the length of the probe is preferably at least about 20 nucleotides, and more preferably, at least about 50 nucleotides, and will not normally exceed about 500 nucleotides. In some instances, it may be advantageous to used mixtures of probes that are complementary to numerous FGFR types and/or subtypes. Probes or mixtures of probes, based on the DNA sequence of any FGFR or mixtures thereof may be prepared. DNA encoding FGFR subtypes and isoforms of FGFRs is known to those of skill in this art (see, e.g.. PCT International Application WO 91/00916 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, July 6, 1989, which is based on U.S. Application Serial No. 07/377,033; Isacchi et aL., "Complete Sequence of a Human Receptor for Acidic and Basic Fibroblast Growth Factors", Nucleic Acid Res.. 18:1906 (1990); Keifer et aL (1991 ) "Molecular Cloning of A Human Basic FGF Receptor cDNA and Expression of a Biologically Active Extracellular Domain in a Baculovirus System", Growth Factors. 05:1 15-1 19: Keegan et aL (1991 ) "Characterization of the FGFR-3 Gene and its Gene Product", Ann. N.Y. Acad. Sci. 638:400-402): Hou et aL (1991 ) "Fibroblast Growth Factor Receptors From Liver Vary in Three Structural Domains", Science. 251:665-668 (1991 ); Partanen et aL (1991 ) "FGFR-4, A Novel Acidic Fibroblast Growth Factor Receptor With Distinct Expression Pattern", EMBO J.. 10:1345-1354; Bergonzoni et a (1992) "Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli". Eur. J. Biochem. 210: 823-829; and Seno et aL (1991 ) "Two cDNAs encoding novel human FGF receptor", Biochim. Biophvs. Acta 1089:244-246). Preferred probes herein include probes that include the sequence of nucleotides or ribonucleotides that have the sequence set forth in SEQ ID NO. 1 or are sufficiently homologous to the DNA of SEQ ID NO. 1 to form stable hybrids under conditions of high stringency. The probe can be labeled to permit its direct detection. While a variety of labels are useful, since the sample to be assayed will typically be a paraffin-embedded section from a tissue biopsy, it is preferred that the label be one which can generate a color reaction when a suitable substrate is added to the section after any unbound probe has been removed by washing. Among suitable labels, therefore, are enzymes which, in the presence of a suitable substrate, generate a color. These include various peroxidases, such as horseradish peroxidase, alkaline phosphatase and the like. Although direct labeling can be used, it is preferred to label the probe with biotin and to treat the hybridized probe with an avidin(or streptavidin)/enzyme complex as described above for the immunostaining process. This procedure can conveniently be done by synthesizing the probe using a nucleotide which is biotinylated. Biotinylated uracil triphosphate is preferred for this purpose. in situ hybridization assays A preferred method for determining the presence of elevated levels of FGFR involves in situ hybridization of a probe, for example, a biotinylated cRNA probe, with mRNA in the target tissue in a standard paraffin-fixed section of biopsy material to detect mRNA encoding an FGFR and thereby detect expression of the gene encoding the mRNA. The probe for in. situ hybridization is preferably a cRNA copy of DNA that includes a sequence of nucleotides, for example, SEQ ID NO 1 , that encodes all or a portion of an FGFR. The probe is hybridized to a fixed section of a biopsied lesion and the resulting hybrids are detected. In the preferred method in which the hybrids contain biotinylated RNA, the hybrids are treated and stained, as set forth in the Examples. Malignant lesions develop a detectable stain. Kits and diagnostic systems The diagnostic systems may be provided in kit form that is useful for detecting FGFR in body fluid sample. The kit for immunological assays contains antibodies, substantially whole antibodies, or antibody combining sites like Fab and F(ab') sub 2 antibody portions that specifically react with an FGFR in one package. The kit also includes an indicating means for signaling the presence of an immunoreaction between the antibody and FGFR. Typical indicating means include radioisotopes such as 125 l, 131 l, enzymes, such as alkaline phosphatase, horseradish peroxidase, beta-D-galactosidase and glucose oxidase, and fluorochrome dyes such as fluorescein and rhodamine. The indicating means may be linked directly to the antibody. The indicating means may also be linked to a separate molecule, such as to a second antibody, to an antibody combining site or another entity that binds to an FGF receptor. The indicating means permits the immunoreaction product to be detected, and is packaged separately from the antibody. The kit may also include additional reagents, such as blocking composition to prevent non-specific binding of the labeled antibody used to the sample. Similarly, kits for performing the hybridization assays herein are provided. Such kits include a probe or mixture of probes that specifically hybridize to one or more FGF receptors. Preferably, such probes will hybridize to the extracellular domain of the receptor. The kit also includes indicating means for detecting the formation of hybrids. As discussed above, the probe is preferably labeled with biotin by synthesizing the probe using a nucleotide, such biotinylated uracil triphosphate. The kit will then also include packaged avidin (or streptavidin)/enzyme complex to treat the resulting hybrids, as described herein, for the immunostaining process. The antibody molecules, probes and separate indicating means of any diagnostic system described herein, may be provided in solution, as a liquid dispersion or as a substantially dry powder, e.g.. in lyophilized form. The indicating means and second antibody or other reagent are packaged separately from the antibody molecules. Where the indicating means is an enzyme, the enzyme's substrate may also be provided in a separate package of the system. A solid support such as the before-described microscope slides and means for paraffin fixing may also be included as separately packaged elements in the diagnostic assay systems. The kits may also include suitable ancillary reagents, such as the appropriate buffers and salts for performing the immunoassays and hybridization reactions. The packages discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic systems. Such packages include glass and plastic, such as, polyethylene, polypropylene and polycarbonate, bottles, vials, plastic and plastic-foil laminated envelopes and the like. The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention. EXAMPLE 1 Immunostaining distinguished malignant melanomas from non-malignant lesion The lesions used in this study were obtained from human biopsy samples. The antibody used in this study was a monoclonal antibody raised against the extracellular domain (SEQ ID NO. 2) of an FGFR 1 (fig 5; see, e.g.. Keifer et al . (1991 ) "Molecular Cloning of A Human Basic FGF Receptor cDNA and Expression of a Biologically Active Extracellular Domain in a Baculovirus System", Growth Factors. 05:1 15-1 19). The clinical terminology and staining determinations, set forth below, are known to those of skill in this art (see, e.g.. W.F. Lever (1990) Histopatholoov of the Skin. 7th ed., J.B. Lippincott Company, Philadelphia). The assays were performed according to the following protocol: 1. Incubate the section in 3% hydrogen peroxide in methanol or phosphate buffered saline (PBS) for three (3) to five (5) minutes (depending on the antibody used) to quench endogenous peroxidase activity. 2. Wash section in phosphate-buffered saline (PBS) containing 0.1-0.5% Triton for 15-30 minutes depending on the antibody used as determined by optimization procedures. 3. Preincubate section for 20 minutes with a 1.5% solution in PBS-0.3% Triton (sigma, St Louis, MO) of a blocking serum containing non-specific antibody of the same species as the second-labeled antibody (e.g., an antibody of murine origin), to saturate non-specific binding sites reactive with the anti-FGFR antibody. 4. Blot excess serum from the section. 5. Incubate section at 4°C for 16-20 hours with "anti-FGFR antibody solution," prepared as described below. 6. After incubation with anti-FGFR, wash section for fifteen (15) minutes with PBS-0.3% Triton to remove non-specifically bound antibody. 7. Incubate section with biotinylated anti-mouse antibody (for example, commercially available from Vector Laboratories, Burlingame, CA) diluted in PBS-0.3% Triton containing 1.5% of the blocking serum of step 3 for 45 minutes at room temperature. 8. Wash section with PBS-0.3% Triton for fifteen (15) minutes. 9. Incubate section for 30 minutes to one (1 ) hour with avidin conjugated with peroxidase (ABC complex for Vector), diluted in PBS-0.3% Triton prepared thirty (30) minutes before use. 10. Wash section with PBS-0.3% Triton™ X-100 (the nonionic detergent octoxynol) for fifteen (15) minutes. 1 1. Incubate section for twenty (20) minutes in peroxidase substrate solution (aminoethylcarbazole from Sigma) in DMSO and 50 mM acetate buffer (pH 5.0), containing 0.01 % hydrogen peroxidase. 12. Wash section in deionized water for ten (10) minutes. 13. Counterstain section with hematoxylin (Fisher Chemicals, Tustin, CA) and mount slide with crystal mount. 14. Read section under a microscope comparing color versus lack of color presentation. Red color development indicates a malignant lesion. As can be seen from Table 1 , using the above-described method, malignant melanocytes stained positively. Benign melanocytes, however, stained negatively, thus establishing that expression of an FGF receptor can serve as a diagnostic marker for a neoplasia. TABLE 1 In situ hybridization of FGFR complementary RNA Probe (biotinylated) to mRNA in biopsy samples distinguished malignant melanomas from non- malignant lesions Lesions were obtained from human biopsy samples and were paraffin fixed on slides. The probe was RNA complementary to the DNA set forth SEQ ID NO. 1 . It corresponds to a portion of the extracellular domain of an FGFR that encodes amino acids 158-277 of SEQ ID NO. 1 , except that the Gly of the protein of SEQ ID NO. 2 is a Ser (residue 12) in the protein encoded by SEQ ID NO. 1. The probe was prepared by inserting double-stranded DNA having the sequence set forth in SEQ ID NO. 1 into the plasmid pSP6/T7-19 (LIFE TECHNOLOGIES, INC. Rockville, MD; see, also U.S. Patent Nos. 5,137,829 and 5,026,645). The DNA was inserted into the plasmid such that transcription from the T7 promoter produced cRNA that hybridized to FGFR-encoding mRNA produced in melanocytic tissues. Transcription of opposite strand produced a sense RNA copy was used as a control. The assays were performed according to the following protocol: 1. Prior to hybridization, the slide on which the paraffin-fixed section of biopsy material was placed was washed with the following reagents: a. xylene (10 min.) b. 100% ethanol (10 min.) c. air dry (10 min.) d. 95% ethanol (2 min.) e. 80% ethanol (2 min.) f. 70% ethanol (2 min.) g. 2 X SSPE buffer 2X (5 min.) (1 X SSPE is pH 7.4 sodium phosphate-buffered 0.18 NaCI; see, e.g.. Sambrook et aL (1989) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press (1989), vol. 3, p. B.13,), h. Proteinase K (10 //ml), 37°C, (30 min.) i. 0.1 M TEA (trichloroethyiacetic acid), 0.25% Acetic Anhydride; (10 min.) j. 2X SSPE buffer, 2X (5 min.) k. 0.1 M Tris/glycine pH 7.0 (30 min.O I. 2X SSPE buffer, 2X (3 min.) m. 70% ethanol (3 min.O n. 95% ethanol (3 min.) o. air dry (2 hrs.) 2. The cRNA probe was diluted to 800 ng/ml with buffer and was applied to slide. The coverslips were placed on the slide; sealed and the slide was incubated overnight at 55 °C on a warm plate. The buffer contained the following ingredients: 5 ml deionized formamide; 2 ml dextran sulfate; 2 ml SSPE (20X); 0.2 ml of 50X Denhardt's reagent (50X Denhardt's reagent contains 5 g Ficoll (Type 400, PHARMACIA FINE CHEMICALS, Uppsala, Sweden), 5g polyvinylpyrrolidone, 5 g bovine serum albumin (Fraction V; SIGMA, Madison, Wl), and H 2 0 to 500 ml); 0.5 ml total RNA (salmon sperm (10 / g/ml)); and 0.25 ml yeast tRNA (10 /g/ml). 3. The slide was rinsed with 4X SSPE for 20 minutes to remove the coverslip followed by 3X 10-minute rinses and the section was then rinsed as follows:. a. 50% formamide/2X SSPE, 2X for 15 minutes at 48°-50°C. b. 2X SSPE buffer, 2X (10 min.) 4. The section was incubated with RNaseA (10 //g/ml), 37°C (30 min.) and rinsed as follows: a. 2X SSPE buffer, 2X (10 min). b. 50% formamide/2X SSPE at 48°-50°C (15 min.) c. 2X SSPE buffer (5 min.) d. 0.1 M Tris Saline (5 min.) 5. The section was incubated with avidin complex with alkaline phosphatase (Vector) for 1 hour at room temperature and then rinsed with 0.1 M Tris saline for 5 minutes (3X). 6. The section was incubated with Fast Red solution for 8 hours (optionally with Levamisole, an inhibitor of endogenous alkaline phosphatase) and then rinsed with deionized water 3X. 7. The section was then counterstained with hematoxylin (optional) and rinsed with deionized water. 8. The section was mounted with crystal mount and read under a microscope. Color development indicates that the sample was a malignant lesion. As shown in Table 2, malignant melanocytes stain positively using the techniques described above. Benign melanocytes stain negatively using the same techniques, thus establishing that there is increased expression of the mRNA in neoplastic cells that hybridizes to DNA encoding a portion of an FGF receptor. TABLE 2 Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Nova, Michael P. Gonzalez, Ana-Maria Baird, Andrew (ii) TITLE OF INVENTION: Process for Detection of Neoplastic Disease (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Fitch, Even, Tabin & Flannery (B) STREET: 135 South LaSalle Street, Suite 900 (C) CITY: Chicago (D) STATE: IL (E) COUNTRY: USA (F) ZIP: 60603 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/900,646 (B) FILING DATE: 18-JUN-1992 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Seidman, Stephanie (B) REGISTRATION NUMBER: 33,779 (C) REFERENCE/DOCKET NUMBER: 54625PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 619-552-1311 (B) TELEFAX: 619-552-0095 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..360 (D) OTHER INFORMATION: /standard name= ""fig probe' (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ACC CCA AAC CCC ACA CTG CGC TGG TTG AAA AAT AGC AAA GAA TTC AAA 48 Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Ser Lys Glu Phe Lys 1 5 10 15 CCT GAC CAC AGA ATT GGA GGC TAC AAG GTC CGT TAT GCC ACC TGG AGC 96 Pro Asp His Arg lie Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser 20 25 30 ATC ATA ATG GAC TCT GTG GTG CCC TCT GAC AAG GGC AAC TAC ACC TGC 144 lie lie Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys 35 40 45 ATT GTG GAG AAT GAG TAC GGC AGC ATC AAC CAC ACA TAC CAG CTG GAT 192 lie Val Glu Asn Glu Tyr Gly Ser lie Asn His Thr Tyr Gin Leu Asp 50 55 60 GTC GTG GAG CGG TCC CCT CAC CGG CCC ATC CTG CAA GCA GGG TTG CCC 240 Val Val Glu Arg Ser Pro His Arg Pro lie Leu Gin Ala Gly Leu Pro 65 70 75 80 GCC AAC AAA ACA GTG GCC CTG GGT AGC AAC GTG GAG TTC ATG TGT AAG 288 Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys 85 90 95 GTG TAC AGT GAC CCG CAG CCG CAC ATC CAG TGG CTA AAG CAC ATC GAG 336 Val Tyr Ser Asp Pro Gin Pro His lie Gin Trp Leu Lys His lie Glu 100 105 110 GTG AAT GGG AGC AAG ATT GGC CCA 360 Val Asn Gly Ser Lys lie Gly Pro 115 120 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 351 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Protein (B) LOCATION: 1..351 (D) OTHER INFORMATION: /note= "Sequence of extracellular domain of an FGFR1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Ser Pro Thr Leu Pro Glu Gin Ala Gin Pro Trp Gly Ala Pro Val Glu 1 5 10 15 Val Glu Ser Phe Leu Val His Pro Gly Asp Leu Leu Gin Leu Arg Cys 20 25 30 Arg Leu Arg Asp Asp Val Gin Ser lie Asn Trp Leu Arg Asp Gly Val 35 40 45 Gin Leu Ala Glu Ser Asn Arg Thr Arg lie Thr Gly Glu Glu Val Glu 50 55 60 Val Gin Asp Ser Val Pro Ala Asp Ser Gly Leu Tyr Ala Cys Val Thr 65 70 75 80 Ser Ser Pro Ser Gly Ser Asp Thr Thr Tyr Phe Ser Val Asn Val Ser 85 90 95 Asp Ala Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Asp Asp Ser Ser 100 105 110 Ser Glu Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Pro Val Ala Pro 115 120 125 Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro 130 135 140 Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn 145 150 155 160 Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp His 165 170 175 Arg lie Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser lie lie Met 180 185 190 Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys lie Val Glu 195 200 205 Asn Glu Tyr Gly Ser lie Asn His Thr Tyr Gin Leu Asp Val Val Glu 210 215 220 Arg Ser Pro His Arg Pro lie Leu Gin Ala Gly Leu Pro Ala Asn Lys 225 230 235 240 Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr Ser 245 250 255 Asp Pro Gin Pro His lie Gin Trp Leu Lys His lie Glu Val Asn Gly 260 265 270 Ser Lys lie Gly Pro Asp Asn Leu Pro Tyr Val Gin lie Leu Lys Thr 275 280 285 Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His Leu Arg 290 295 300 Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn 305 310 315 320 Ser lie Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu Glu Ala 325 330 335 Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu 340 345 350

Claims: WHAT IS CLAIMED: 1. A process for detecting neoplastic disease in a subject, comprising detecting in a sample obtained from the subject a product indicative of elevated expression of a fibroblast growth factor receptor gene or a product indicative of elevated amounts of fibroblast growth factor receptor, wherein detection of the product indicates the presence of neoplastic disease in the subject. 2. The process of claim 1 , wherein the detection of the product is accomplished by: (a) contacting a sample obtained from said subject with an agent having specificity for said product; and (b) detecting the binding of said agent to said product, wherein the detection of the binding of said agent indicates the presence of said neoplastic disease. 3. The process of claim 2, wherein said agent is an antibody or a functional fragment thereof. 4. The process of claim 2, wherein said agent is a nucleic acid probe. 5. The process of claim 2, wherein said agent is labelled with a detectable marker. 6. The process of any of claims 1-5, wherein the product is a receptor protein. 7. The process of any of claims 1 , 2, 5 and 6, wherein the process is an immunoassay. 8. The process of claim 7, comprising: treating a paraffin-fixed section of biopsy material with an antibody having specific reactivity with the receptor protein, removing unbound antibody from the section and detecting the antibody bound to receptor protein present in the section, wherein the detection of antibody bound to said receptor protein indicates the presence of neoplastic disease in said subject. 9. The process of claim 8, wherein the bound antibody is detected by: (a) incubating the section with a second antibody that binds to the first antibody, wherein said second antibody is detectably labelled; (b) removing unbound second antibody from the section; and (c) detecting complexes containing the second antibody. 10. The process of any of claims 1 , 2 and 4-6, wherein the product is mRNA or cDNA that encodes the receptor protein. 1 1. A process according to claim 10, wherein the mRNA or cDNA is detected by hybridization with a detectable nucleic acid probe having a nucleotide sequence sufficiently complementary to at least a portion of the mRNA or cDNA to hybridize thereto. 12. The process of claim 4 or claim 1 1 , wherein the probe is biotinylated. 13. The process of claim 4 or claim 11 , wherein the probe is labeled with digoxin. 14. The process of any of claims 1 1-13, wherein hybridization of the probe to mRNA in the sample is detected by: (a) removal of unbound probe from the section; (b) incubation of the section with a complex of avidin or streptavidin and alkaline phosphatase; (c) removal of unbound avidin or streptavidin/alkaline phosphatase complex from the section; (d) treatment of the section with a color forming substrate for alkaline phosphatase; (e) removal of unbound substrate; and (f) reading the section to determine the presence of neoplastic disease. 15. The method of claim 9, wherein the second antibody is biotinylated; and following removal of unbound second antibody the section is incubated with a complex of avidin or streptavidin and peroxidase; the unbound avidin or streptavidin/peroxidase complex is removed; the section is treated with a color forming substrate for peroxidase; the unbound substrate is removed; and complexes are detected by reading the section to detect any color change to determine the presence of neoplastic disease. 16. The process of any of claims 1-15, wherein the neoplastic disease is malignant melanoma. 17. The process of any of claims 4 or 10-16, wherein the probe includes nucleotides or ribonucleotides that have the sequence set forth in SEQ ID NO. 1 or are sufficiently homologous to the DNA of SEQ ID NO. 1 to form stable hybrids under conditions of high stringency. 18. A kit for diagnosing neoplastic disease, comprising: (a) a first antibody that specifically reacts with one ore more fibroblast growth factor receptors (FGFRs); (b) indicating means for detecting immunoreaction between the antibody and an FGFR; (c) reagents for performing direct immunostaining of biopsied tissue samples. 19. A kit for diagnosing neoplastic disease, comprising: (a) one or more nucleic acid probes that selectively hybridize to one ore more human fibroblast growth factor receptors (FGFRs); (b) indicating means for detecting hybrids between the probes and mRNA or cDNA encoding all or a detectable portion of an FGFR; and (b) reagents for in situ hybridization with cell or tissue samples. 20. The kit of claim 18 or 19, wherein the neoplastic disease is malignant melanoma. 21. The kit of claim 18 or 19, wherein the antibody specifically binds to the extracellular domain of a fibroblast growth factor receptor. 22. The kit of claim 18, 20 or 21 , further comprising a second that specifically binds to the first antibody. 23. The kit of claim 19 or 20, wherein the probe specifically hybridizes to DNA encoding the extracellular domain of a fibroblast growth factor receptor. 24. The kit of any of claims 18, 21 and 22, wherein the probe includes nucleotides or ribonucleotides that have the sequence set forth in SEQ ID NO. 1 or are sufficiently homologous to the DNA of SEQ ID NO. 1 to form stable hybrids under conditions of high stringency. 25. The kit of any of claims 19, 20, 21 , 22, or 23, wherein the reagents include a blocker that prevents non-specific binding of the antibody to the tissue sample. 26. The kit of any of claims 18, 20-22 and 25, wherein the antibody specifically reacts with the protein having SEQ ID NO. 2 or the protein encoded by SEQ ID NO. 1. 27. The process of any of claims 1-7, 10-14, 16 and 17, wherein the sample is blood, urine, a blood fraction or cerebral spinal fluid. 28. The process of any of claims 1-17, wherein the sample is biopsied tissue.

Inventors: BAIRD J ANDREW, GONZALEZ ANA-MARIA, NOVA MICHAEL PHILIP, BAIRD, J., ANDREW, GONZALEZ, ANA-MARIA, NOVA, MICHAEL, PHILIP
Applicants: BAIRD J ANDREW, GONZALEZ ANA MARIA, NOVA MICHAEL PHILIP, PRIZM PHARMA INC, WHITTIER INST DIABETES & ENDOC, PRIZM PHARMACEUTICALS, INC., WHITTIER INSTITUTE FOR DIABETES AND ENDOCRINOLOGY
Application year: 1993
Main classification: C12Q1
IPC codes: C07K14, C12Q1, G01N33